Menaka Sarav, MD, DipABLM
she/her/hers
Assistant Professor of Medicine (Nephrology)Cards
About
Research
Publications
2025
Divergent GFR Estimates and Clinical Implications
Sarav M, Alpern R. Divergent GFR Estimates and Clinical Implications. JAMA: The Journal Of The American Medical Association 2025, 334: 1888-1890. PMID: 41202183, DOI: 10.1001/jama.2025.14043.Peer-Reviewed Original ResearchIntegrating Lifestyle and Nutrition into CKD Care: Physician-Led Kidney Nutrition Program at Yale
Kurian R, Sarav M. Integrating Lifestyle and Nutrition into CKD Care: Physician-Led Kidney Nutrition Program at Yale. Journal Of The American Society Of Nephrology 2025, 36: 10.1681/asn.20257ygkvyav. DOI: 10.1681/asn.20257ygkvyav.Peer-Reviewed Original ResearchDeclining Serum Albumin With Stable Body Mass Index: A Mortality Indicator in Predialysis Chronic Kidney Disease
Sarav M, Shrestha P, Naseer A, Thomas F, Sumida K, Kalantar-Zadeh K, Kovesdy C. Declining Serum Albumin With Stable Body Mass Index: A Mortality Indicator in Predialysis Chronic Kidney Disease. Journal Of Renal Nutrition 2025, 35: 598-606. PMID: 40339729, PMCID: PMC12353537, DOI: 10.1053/j.jrn.2025.04.005.Peer-Reviewed Original ResearchStable body mass indexAdvanced chronic kidney diseaseBody mass indexChronic kidney diseaseCohort of US veteransPre-dialysis chronic kidney diseasePredialysis chronic kidney diseaseClinically relevant declineChronic kidney disease managementComprehensive nutritional assessmentSerum albumin levelAfrican American participantsProportion of patientsDialysis chronic kidney diseaseCox proportional hazards modelsKidney replacement therapySerum albumin measurementProportional hazards modelMortality indicatorsPredialysis periodUS veteransReplacement therapyAlbumin levelsNutritional markersNationwide cohort
2024
Declining Serum Albumin in the Shadow of Stable Body Mass Index: A Mortality Indicator in Predialysis CKD
Sarav M, Shrestha P, Naseer A, Thomas F, Sumida K, Kalantar-Zadeh K, Kovesdy C. Declining Serum Albumin in the Shadow of Stable Body Mass Index: A Mortality Indicator in Predialysis CKD. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024f9m577ph. DOI: 10.1681/asn.2024f9m577ph.Peer-Reviewed Original ResearchIMPLEMENTING ADHERENCE TO SGLT2I AND GLP1RA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FINDINGS FROM A PHARMACIST-DRIVEN CARDIODIABETES CLINIC PROGRAM
Lee K, Ikram M, Mishkel G, Ng E, Krupa E, Zahvolskyy L, Davidson D, Gordon R, Billings L, Sarav M, Block R, Erwin J, Qamar A. IMPLEMENTING ADHERENCE TO SGLT2I AND GLP1RA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FINDINGS FROM A PHARMACIST-DRIVEN CARDIODIABETES CLINIC PROGRAM. Journal Of The American College Of Cardiology 2024, 83: 1938. DOI: 10.1016/s0735-1097(24)03928-7.Peer-Reviewed Original Research
2023
Peritoneal Dialysis-Related Peritonitis With Acinetobacter Pittii: A Case Report
Bajaj T, Ismail N, Trivedi A, Sarav M. Peritoneal Dialysis-Related Peritonitis With Acinetobacter Pittii: A Case Report. Journal Of Investigative Medicine High Impact Case Reports 2023, 11: 23247096221148264. PMID: 36624661, PMCID: PMC9834918, DOI: 10.1177/23247096221148264.Peer-Reviewed Original ResearchConceptsPeritoneal dialysis (PD)-related peritonitisPeritoneal dialysis-related peritonitisSensitive to ceftazidimeEnd-stage renal diseaseNidus of infectionIntraperitoneal antibioticsPD catheterWorsening infectionCase reportSevere infectionsRenal diseasePeritonitisInfectionAcinetobacter pittiiSterile techniqueYoung menHand hygieneComplex groupGroup of organismsCeftazidimeComplex group of organismsCatheterPatientsNidusReports
2022
Peritoneal Dialysis Peritonitis With Acinetobacter pittii
Bajaj T, Ismail N, Trivedi A, Sarav M. Peritoneal Dialysis Peritonitis With Acinetobacter pittii. Journal Of The American Society Of Nephrology 2022, 33: 455-455. DOI: 10.1681/asn.20223311s1455c.Peer-Reviewed Original ResearchResults from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin B, Fragale G, Karl A, Losisolo P, Trimarchi H, Hoyos I, Lampo M, Monkowski M, De La Fuente J, Alvarez M, Stoppa D, Chiurchiu C, Novoa P, Orias M, Barron M, Giotto A, Arriola M, Cassini E, Maldonado R, Dionisi M, Ryan J, Toussaint N, Luxton G, Peh C, Levidiotis V, Francis R, Phoon R, Fedosiuk E, Toropilov D, Yakubtsevich R, Mikhailova E, Bovy C, Demoulin N, Hougardy J, Maes B, Speeckaert M, Laurin L, Barbour S, Masse M, Hladunewich M, Reich H, Cournoyer S, Tennankore K, Barbour S, Lv J, Liu Z, Wang C, Li S, Luo Q, Ni Z, Yan T, Fu P, Cheng H, Liu B, Lu W, Wang J, Chen Q, Wang D, Xiong Z, Chen M, Xu Y, Wei J, Pai P, Chen L, Rehorova J, Maixnerova D, Safranek R, Rychlik I, Hruby M, Makela S, Vaaraniemi K, Ortiz F, Alamartine E, Daroux M, Cartery C, Vrtovsnik F, Serre J, Stamellou E, Vielhauer V, Hugo C, Budde K, Otte B, Nitschke M, Ntounousi E, Boletis I, Papagianni A, Goumenos D, Stylianou K, Zermpala S, Esposito C, Cozzolino M, Viganò S, Gesualdo L, Nowicki M, Stompor T, Kurnatowska I, Kim S, Kim Y, Na K, Kim D, Kim S, Porras L, Garcia E, Pamplona I, Segarra A, Goicoechea M, Fellstrom B, Lundberg S, Hemmingsson P, Guron G, Sandell A, Chen C, Tokgoz B, Duman S, Altiparmak M, Ergul M, Maxwell P, Mark P, McCafferty K, Khwaja A, Cheung C, Hall M, Power A, Kanigicherla D, Baker R, Moriarty J, Mohamed A, Aiello J, Canetta P, Ayoub I, Robinson D, Thakar S, Mottl A, Sachmechi I, Fischbach B, Singh H, Mulhern J, Kamal F, Linfert D, Rizk D, Wadhwani S, Sarav M, Campbell K, Coppock G, Luciano R, Sedor J, Avasare R, Lau W. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International 2022, 103: 391-402. PMID: 36270561, DOI: 10.1016/j.kint.2022.09.017.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsSecondary efficacy outcomesTwo-part trialGlomerular filtration rateMonths of treatmentPart AEGFR preservationOral budesonidePrimary IgANEfficacy outcomesNephropathy TrialPrimary endpointAdult patientsAdverse eventsCreatinine ratioIgA nephropathyKidney failureUrine proteinFiltration ratePlaceboTherapeutic potentialPrimary immunoglobulinUPCRMonthsTrials
2020
Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies.
Sullivan K, Kaminer L, Grinblatt D, Campbell N, Nocon C, Harper A, Kang J, Sarav M, Curtis B, Brockstein B. Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies. JCO Oncology Practice 2020, 17: 153-155. PMID: 33270522, DOI: 10.1200/op.20.00734.Peer-Reviewed Original ResearchAcute Kidney Injury Incidence in Hospitalized Patients and Implications for Nutrition Support
Meyer D, Mohan A, Subev E, Sarav M, Sturgill D. Acute Kidney Injury Incidence in Hospitalized Patients and Implications for Nutrition Support. Nutrition In Clinical Practice 2020, 35: 987-1000. PMID: 33140897, DOI: 10.1002/ncp.10595.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAdult patientsRates of acute kidney injuryHospitalized patientsAcute kidney injury incidenceManagement of acute kidney injuryMultiple nutritional problemsAdequate nutritional supportHospitalized adult patientsKidney injuryNutritional supportPatientsNutritional problemsIncidenceInjury incidence
Clinical Care
Overview
Menaka Sarav, MD, is a nephrologist specializing in the treatment of complex kidney conditions, with a particular focus on glomerulonephritis (inflammation of the tiny filtering units in the kidneys) and proteinuric kidney disease (a condition where excessive protein is found in the urine, indicating possible kidney damage).
She uses a variety of approaches to improve health outcomes, including emphasizing nutrition to slow the progression of kidney disease.
As an assistant professor at Yale School of Medicine, Dr. Sarav is involved in research aimed at enhancing the understanding of renal diseases through clinical trials and informatics tools. Her research includes investigating the mechanisms of proteinuria and immune complex processing in the kidney.
Dr. Sarav received her medical training from Bangalore University in India and completed her residency in internal medicine at St. Francis Hospital. She furthered her expertise with a nephrology clinical fellowship and a postdoctoral research fellowship at the University of Chicago. Additionally, she pursued a clinical nutrition fellowship through the American Society of Parenteral and Enteral Nutrition and the Nestlé Nutrition Institute.
Clinical Specialties
Nephrology
News
Get In Touch
Contacts
Appointment Number
Mailing Address
Nephrology
330 Cedar Street, Boardman Bldg
New Haven, CT 06510
United States
Administrative Support
Locations
Boardman Building
Academic Office
330 Cedar Street
New Haven, CT 06510
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.